Absence of anti-trifluoroacetate antibody after halothane anaesthesia in patients exhibiting no or mild liver damage.
It has been shown that the circulating antibodies, which bind to rat hepatic microsomal proteins obtained after in vivo exposure to halothane, are detectable by immunoblotting in patients with "halothane hepatitis (HH)," and that rabbit immunized anti-sera against trifluoroacetylated rabbit serum albumin (TFA-RSA) recognizes rat microsomal distorted polypeptides in almost the same way as do sera from patients with HH. In this paper, we report first the development of a novel method of synthesizing TFA-RSA using p-nitrophenyl TFA, and second the results of tests for circulating anti-TFA antibodies in the serum of 86 patients who had received halothane anaesthesia and developed no (67 patients) or mild (19 patients, the maximum activity of serum alanine aminotransaminase 519 IU.L-1) liver damage. Serum was selected from stored sera of post-transfusion patients. The new method of synthesizing TFA-RSA was convenient and was able to be done at neutral pH. Rabbit sera obtained after immunization with the newly synthesized TFA-RSA recognized the same polypeptides (109 kDa, 92 kDa, 80 kDa, 76 kDa, 64 kDa and 59 kDa) as the established anti-sera against TFA-RSA, and these reactions were inhibited in the presence of TFA-lysine. Circulating antibodies were not detected in our patients who had developed no or mild liver damage. The present finding supports the hypothesis that the appearance of circulating antibodies against microsomal distorted proteins are specific to patients with HH. Furthermore, we have shown here that the halothane-induced mild increase in ALT activity is not associated with the appearance of those circulating antibodies, supporting the pathophysiological difference between HH and halothane-induced mild hepatic damage.
Sakaguchi
Y
Y
Department of Anesthesiology and Critical Care Medicine, Faculty of Medicine, Kyushu University, Japan.
Inaba
S
S
Irita
K
K
Sakai
H
H
Nawata
H
H
Takahashi
S
S
D000293:Adolescent; D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D000769:Anesthesia, Inhalation; D000818:Animals; D000906:Antibodies / Q000097:blood*; D056486:Chemical and Drug Induced Liver Injury / Q000097:blood / Q000209:etiology / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D004591:Electrophoresis, Polyacrylamide Gel; D005260:Female; D006221:Halothane / Q000009:adverse effects; D006801:Humans; D015151:Immunoblotting; D007223:Infant; D017093:Liver Failure / Q000097:blood / Q000139:chemically induced / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011817:Rabbits; D051381:Rats; D017208:Rats, Wistar; D012709:Serum Albumin; D014269:Trifluoroacetic Acid / Q000276:immunology*
D000906:Antibodies; D012709:Serum Albumin; D014269:Trifluoroacetic Acid; D000410:Alanine Transaminase; D006221:Halothane